Overview

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Status:
Completed

Trial end date:
2018-01-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC02 in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Alnylam Pharmaceuticals